Biotech Values

[DewDiligence]

FDA approves LLY’s Zepbound—(tirzepatide)—for weight loss and chronic weight management:

https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-zepboundtm-tirzepatide-chronic-weight

Zepbound is the same drug as LLY’s Mounjaro, which is approved for T2D. The FDA dosing recommendation for Zepbound is 5mg, 10mg, or 15mg once weekly by subcutaneous injection—titrated upward from the starting dose of 2.5mg weekly in increments of 2.5mg weekly. This is essentially the same dosing as in the FDA label for Mounjaro.

Zepbound FDA label:
https://c212.net/c/link/?t=0&l=en&o=4017561-1&h=1423994038&u=https%3A%2F%2Fpi.lilly.com%2Fus%2Fzepbound-uspi.pdf&a=Prescribing+Information